國立虎尾科技大學 |

RNA metabolism in neurodegenerative diseases

Record Type:	Language materials, printed : Monograph/item
Title/Author:	RNA metabolism in neurodegenerative diseases/ edited by Rita Sattler, Christopher J. Donnelly.
other author:	Sattler, Rita.
Published:	Cham :Springer International Publishing : : 2018.,
Description:	xx, 310 p. :digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Nervous system - Degeneration. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-89689-2
ISBN:	9783319896892

RNA metabolism in neurodegenerative diseases
RNA metabolism in neurodegenerative diseases[electronic resource] /edited by Rita Sattler, Christopher J. Donnelly. - Cham :Springer International Publishing :2018. - xx, 310 p. :digital ;24 cm. - Advances in neurobiology,v.202190-5215 ;. - Advances in neurobiology ;6..

RNA Metabolism in Neurodegenerative Diseases -- Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes -- RNA Editing Deficiency in Neurodegeneration -- RNA Nucleocytoplasmic Transport Defects in Neurodegenerative Diseases -- RNA Degradation in Neurodegenerative Disease -- RNP Assembly Defects in Spinal Muscular Atrophy -- Stress Granules and ALS: A Case of Causation or Correlation? -- Deregulation of RNA Metabolism in Microsatellite Expansion Diseases -- Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD -- Senataxin, a Novel Helicase at the Interface of RNA Transcriptome Regulation and Neurobiology: From Normal Function to Pathological Roles in Motor Neuron Disease and Cerebellar Degeneration -- Lost in Translation - Evidence for Protein Synthesis Deficits in ALS/FTD and Related Neurodegenerative Diseases.

It has become evident over the last years that abnormalities in RNA processing play a fundamental part in the pathogenesis of neurodegenerative diseases. Cellular viability depends on proper regulation of RNA metabolism and subsequent protein synthesis, which requires the interplay of many processes including transcription, pre-mRNA splicing, mRNA editing as well as mRNA stability, transport and translation. Dysfunction in any of these processes, often caused by mutations in the coding and non-coding RNAs, can be very destructive to the cellular environment and consequently impair neural viability. The result of this RNA toxicity can lead to a toxic gain of function or a loss of function, depending on the nature of the mutation. For example, in repeat expansion disorders, such as the newly discovered hexanucleotide repeat expansion in theC9orf72 gene found in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a toxic gain of function leads to the formation of RNA foci and the sequestration of RNA binding proteins (RBPs) This in return leads to a loss of function of those RBPs, which is hypothesized to play a significant part in the disease progression of ALS and FTD. Other toxicities arising from repeat expansions are the formation of RNA foci, bi-directional transcription and production of repeat associated non-ATG (RAN) translation products. This book will touch upon most of these disease mechanisms triggered by aberrant RNA metabolism and will therefore provide a broad perspective of the role of RNA processing and its dysfunction in a variety of neurodegenerative disorders, including ALS, FTD, Alzheimer's disease, Huntington's disease, spinal muscular atrophy, myotonic dystrophy and ataxias. The proposed authors are leading scientists in the field and are expected to not only discuss their own work, but to be inclusive of historic as well as late breaking discoveries. The compiled chapters will therefore provide a unique collection of novel studies and hypotheses aimed to describe the consequences of altered RNA processing events and its newest molecular players and pathways.

ISBN: 9783319896892

Standard No.: 10.1007/978-3-319-89689-2doiSubjects--Topical Terms:

668516
Nervous system
--Degeneration.

LC Class. No.: RC365

Dewey Class. No.: 616.8047

RNA metabolism in neurodegenerative diseases
LDR:03984nam a2200325 a 4500 001 926831
003 DE-He213
005 20181227102612.0
006 m d
007 cr nn 008maaau
008 190626s2018 gw s 0 eng d
020 $a 9783319896892 $q (electronic bk.)
020 $a 9783319896885 $q (paper)
024 7 $a 10.1007/978-3-319-89689-2 $2 doi
035 $a 978-3-319-89689-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC365
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
082 0 4 $a 616.8047 $2 23
090 $a RC365 $b .R627 2018
245 0 0 $a RNA metabolism in neurodegenerative diseases $h [electronic resource] / $c edited by Rita Sattler, Christopher J. Donnelly.
260 $a Cham : $c 2018. $b Springer International Publishing : $b Imprint: Springer,
300 $a xx, 310 p. : $b digital ; $c 24 cm.
490 1 $a Advances in neurobiology, $x 2190-5215 ; $v v.20
505 0 $a RNA Metabolism in Neurodegenerative Diseases -- Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes -- RNA Editing Deficiency in Neurodegeneration -- RNA Nucleocytoplasmic Transport Defects in Neurodegenerative Diseases -- RNA Degradation in Neurodegenerative Disease -- RNP Assembly Defects in Spinal Muscular Atrophy -- Stress Granules and ALS: A Case of Causation or Correlation? -- Deregulation of RNA Metabolism in Microsatellite Expansion Diseases -- Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD -- Senataxin, a Novel Helicase at the Interface of RNA Transcriptome Regulation and Neurobiology: From Normal Function to Pathological Roles in Motor Neuron Disease and Cerebellar Degeneration -- Lost in Translation - Evidence for Protein Synthesis Deficits in ALS/FTD and Related Neurodegenerative Diseases.
520 $a It has become evident over the last years that abnormalities in RNA processing play a fundamental part in the pathogenesis of neurodegenerative diseases. Cellular viability depends on proper regulation of RNA metabolism and subsequent protein synthesis, which requires the interplay of many processes including transcription, pre-mRNA splicing, mRNA editing as well as mRNA stability, transport and translation. Dysfunction in any of these processes, often caused by mutations in the coding and non-coding RNAs, can be very destructive to the cellular environment and consequently impair neural viability. The result of this RNA toxicity can lead to a toxic gain of function or a loss of function, depending on the nature of the mutation. For example, in repeat expansion disorders, such as the newly discovered hexanucleotide repeat expansion in theC9orf72 gene found in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a toxic gain of function leads to the formation of RNA foci and the sequestration of RNA binding proteins (RBPs) This in return leads to a loss of function of those RBPs, which is hypothesized to play a significant part in the disease progression of ALS and FTD. Other toxicities arising from repeat expansions are the formation of RNA foci, bi-directional transcription and production of repeat associated non-ATG (RAN) translation products. This book will touch upon most of these disease mechanisms triggered by aberrant RNA metabolism and will therefore provide a broad perspective of the role of RNA processing and its dysfunction in a variety of neurodegenerative disorders, including ALS, FTD, Alzheimer's disease, Huntington's disease, spinal muscular atrophy, myotonic dystrophy and ataxias. The proposed authors are leading scientists in the field and are expected to not only discuss their own work, but to be inclusive of historic as well as late breaking discoveries. The compiled chapters will therefore provide a unique collection of novel studies and hypotheses aimed to describe the consequences of altered RNA processing events and its newest molecular players and pathways.
650 0 $a Nervous system $x Degeneration. $3 668516
650 0 $a RNA $x Metabolism. $3 884442
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Neurosciences. $3 593561
700 1 $a Sattler, Rita. $3 1205735
700 1 $a Donnelly, Christopher J. $3 1205736
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Advances in neurobiology ; $v 6. $3 884407
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-89689-2
950 $a Biomedical and Life Sciences (Springer-11642)